Eaton Bruce 4
4 · Editas Medicine, Inc. · Filed Mar 6, 2023
Insider Transaction Report
Form 4
Eaton Bruce
EVP, Chief Business Officer
Transactions
- Award
Common Stock
2023-03-02+16,700→ 77,683 total - Sale
Common Stock
2023-03-03$8.89/sh−101$898→ 77,582 total - Award
Stock Option (right to buy)
2023-03-02+50,000→ 50,000 totalExercise: $8.72Exp: 2033-03-01→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
- [F2]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
- [F3]This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.